We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PerkinElmer Inc. reported third-quarter 2017 adjusted earnings of 73 cents per share, beating the Zacks Consensus Estimate of 72 cents.
The company, based in Waltham, MA, reported adjusted revenues of approximately $554 million, which beat the Zacks Consensus Estimate of $552 million. Revenues also surpassed the year-ago figure of $548 million.
Segment Details
Revenues from Discovery & Analytical Solutions (DAS) totaled $385.4 million in the third quarter, up 4% from $365.1 million in the year-ago quarter.
Meanwhile, operating profit margin, as a percentage of revenues, was 16.1% compared with the prior-year quarter’s level of 16.2%.
In the Diagnostics segment, revenues were $168.9 million as compared with $149.4 million in the year-ago quarter. This reflects a 5% increase organically.
Meanwhile, operating profit margin for the segment, as a percentage of revenues, was 33.5% compared with 33.8% in the year-ago quarter.
PerkinElmer, Inc. Price, Consensus and EPS Surprise
Adjusted gross margin, as a percentage of revenues, was 49.8% in the quarter, down 10 basis points (bps) year over year. The deterioration was a result of acquisitions and divestitures executed in 2016.
Adjusted selling, general & administrative (SG&A) expenses, as a percentage of revenues, were 24.2%, down 80 bps from the year-ago quarter.
Research and Development (R&D) expenses, as a percentage of revenues, rose 40 bps in the third quarter to $34.9 million.
As a result, the company’s overall adjusted operating margin from continuing operations was 19.3% of net revenues, up 30 bps on a year-over-year basis.
Financial Details
In the first nine months of 2017, PerkinElmer’s operating cash flow from continuing operations was $165 million. The company concluded the quarter with approximately $1.1 billion in debt and $709 million in cash.
Guidance Raised
The company revised its adjusted earnings guidance for full-year 2017. PerkinElmer now expects adjusted earnings per share in the band of $2.87-$2.89, compared with the previous range of $2.84-$2.92.
Zacks Rank & Key Picks
PerkinElmer has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported second-quarter fiscal 2018 earnings of 43 cents, up 79.2% from 24 cents in the year-ago quarter. Gross margin expanded 548 bps year over year to 35.2%.
Luminex reported third-quarter 2017 adjusted earnings of 19 cents, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted third-quarter 2017 adjusted earnings of $2.77, up 34.5% on a year-over-year basis. Revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
PerkinElmer Inc. reported third-quarter 2017 adjusted earnings of 73 cents per share, beating the Zacks Consensus Estimate of 72 cents.
The company, based in Waltham, MA, reported adjusted revenues of approximately $554 million, which beat the Zacks Consensus Estimate of $552 million. Revenues also surpassed the year-ago figure of $548 million.
Segment Details
Revenues from Discovery & Analytical Solutions (DAS) totaled $385.4 million in the third quarter, up 4% from $365.1 million in the year-ago quarter.
Meanwhile, operating profit margin, as a percentage of revenues, was 16.1% compared with the prior-year quarter’s level of 16.2%.
In the Diagnostics segment, revenues were $168.9 million as compared with $149.4 million in the year-ago quarter. This reflects a 5% increase organically.
Meanwhile, operating profit margin for the segment, as a percentage of revenues, was 33.5% compared with 33.8% in the year-ago quarter.
PerkinElmer, Inc. Price, Consensus and EPS Surprise
PerkinElmer, Inc. Price, Consensus and EPS Surprise | PerkinElmer, Inc. Quote
Margin Details
Adjusted gross margin, as a percentage of revenues, was 49.8% in the quarter, down 10 basis points (bps) year over year. The deterioration was a result of acquisitions and divestitures executed in 2016.
Adjusted selling, general & administrative (SG&A) expenses, as a percentage of revenues, were 24.2%, down 80 bps from the year-ago quarter.
Research and Development (R&D) expenses, as a percentage of revenues, rose 40 bps in the third quarter to $34.9 million.
As a result, the company’s overall adjusted operating margin from continuing operations was 19.3% of net revenues, up 30 bps on a year-over-year basis.
Financial Details
In the first nine months of 2017, PerkinElmer’s operating cash flow from continuing operations was $165 million. The company concluded the quarter with approximately $1.1 billion in debt and $709 million in cash.
Guidance Raised
The company revised its adjusted earnings guidance for full-year 2017. PerkinElmer now expects adjusted earnings per share in the band of $2.87-$2.89, compared with the previous range of $2.84-$2.92.
Zacks Rank & Key Picks
PerkinElmer has a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . Notably, PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), while Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported second-quarter fiscal 2018 earnings of 43 cents, up 79.2% from 24 cents in the year-ago quarter. Gross margin expanded 548 bps year over year to 35.2%.
Luminex reported third-quarter 2017 adjusted earnings of 19 cents, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted third-quarter 2017 adjusted earnings of $2.77, up 34.5% on a year-over-year basis. Revenues increased 18% year over year to $806.1 million.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>